An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...
Please provide your email address to receive an email when new articles are posted on . Venetoclax in combination with 5 + 2 induction chemotherapy appeared safe for fit, older patients with acute ...
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma To our knowledge, this is the ...
Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...
After decades in which no novel therapeutic treatments were approved for acute myeloid leukemia (AML), the past few years have seen the approval of several groundbreaking therapies for the disease. 1 ...
The study covered in this summary was published on ssrn.com as a preprint and has not yet been peer reviewed. Cytarabine plus an anthracycline has been the standard AML induction regimen for decades, ...
Adding the targeted therapy venetoclax (Venclexta, AbbVie) to high-dose chemotherapy is a "step forward" for pediatric patients with relapsed or refractory acute myeloid leukemia (AML), says an expert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results